Spruce Biosciences, Inc. SPRB
At closeNov 4, 2026, 4:01 PM EST
After hours · Nov 4, 4:01 PM ET
- YTD
- -46.49%
- 1 year
- -55.58%
- Market cap
- 133.96M
- Revenue (ttm)
- 7.10M
- EPS (ttm)
- -39.12
- Shares out
- 41.30M
- Forward P/E
- -0.41
- YTD return
- -46.49%
- 1-year return
- -55.58%
- Volume
- 51.95K
- Avg volume
- 82.58K
- Open
- 44.43
- Previous close
- 42.81
- Day's range
- 44.43 – 46.61
- 52-week range
- 38.06 – 129.00
- Analysts
- Hold
- Price target
- 1.83 (-96.1%)
- Earnings date
- Aug 12, 2024
2Y -2,963.54 (-98.48%)
Key statistics
- Enterprise value
- -40.58M
- PEG ratio
- 0.00
- Price / sales
- 2.20
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -80.40%
- Free cash flow
- -35.07M
- Total cash
- 60.05M
- Total debt
- 2.96M
- Return on equity
- -57.55%
- Short % of float
- 0.08%
- 50-day average
- 0.50446
- 200-day average
- 0.668845
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 1.83
- Target (high)
- 3.00
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.205.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.27 | -0.21 | +0.06 | +22.22% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.22 | +0.11 | +33.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.32 | -0.28 | +0.04 | +12.50% |
| May 13, 2024 | Mar 1, 2024 | -0.32 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | reit | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sprucebiosciences.com
News
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference 
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference 
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting 
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target 
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149 
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference 
Spruce Biosciences Announces Launch of MPS3BStudy.com 
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B 
Spruce Biosciences Announces Launch of MPS3BStudy.com 
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Your note
Sign in to keep a note on SPRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARLTON RALPH WILLIAM III | Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 161,339 |
| GHARIB SAMIR M | President | Conversion of Exercise of derivative security | Dec 15, 2024 | 350,550 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 20, 2024 | 2,550,000 |
| O DONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| ODONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| SZWARCBERG JAVIER B M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 467,191 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rivervest Venture Management LLC | 7.11% | 2,936,281 | 1.11M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.01% | 2,896,518 | 1.09M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.32% | 2,609,125 | 984.94K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.05% | 1,259,151 | 475.33K | Sep 29, 2024 |
| Vanguard Group Inc | 2.04% | 843,844 | 318.55K | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 1.91% | 787,007 | 297.10K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 638,558 | 241.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 197,187 | 74.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 153,228 | 57.84K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 40,000 | 15.10K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 36,510 | 13.78K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 31,503 | 11.89K | Oct 30, 2024 |